1. Home
  2. DLPN vs SCYX Comparison

DLPN vs SCYX Comparison

Compare DLPN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dolphin Entertainment Inc.

DLPN

Dolphin Entertainment Inc.

N/A

Current Price

$1.60

Market Cap

20.6M

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.87

Market Cap

32.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLPN
SCYX
Founded
1996
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.6M
32.6M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
DLPN
SCYX
Price
$1.60
$0.87
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
33.2K
328.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
27.81
61.36
EPS
N/A
N/A
Revenue
$51,684,984.00
$257,000.00
Revenue This Year
$10.62
$90.24
Revenue Next Year
$13.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.85
N/A
52 Week Low
$0.75
$0.57
52 Week High
$1.88
$1.29

Technical Indicators

Market Signals
Indicator
DLPN
SCYX
Relative Strength Index (RSI) 44.21 62.21
Support Level $1.51 $0.69
Resistance Level $1.71 $0.88
Average True Range (ATR) 0.06 0.06
MACD -0.01 0.01
Stochastic Oscillator 8.07 72.97

Price Performance

Historical Comparison
DLPN
SCYX

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: